Literature DB >> 3232991

Two minute walking distance in cystic fibrosis.

C J Upton1, J C Tyrrell, E J Hiller.   

Abstract

We have evaluated the 'two minute walking distance' in children with cystic fibrosis as an objective measurement of exercise tolerance. There was a strong correlation between walking distance and height in 89 normal children (r = 0.72). Fifty children with cystic fibrosis showed a similar correlation (r = 0.56) with a mean result of 94% of that expected for height compared with the normal children. There was a training effect in the normal children with the second walk being significantly better than the first, but this was not evident in children with cystic fibrosis. The test was reproducible with no significant change in 12 children retested after one to three months. Sixteen children with cystic fibrosis admitted for treatment of chest disease showed a significant improvement in walking distance with treatment. Children as young as 5 years old can perform a walking distance test. It seems to be an objective way of assessing exercise tolerance and can help in evaluating response to treatment.

Entities:  

Mesh:

Year:  1988        PMID: 3232991      PMCID: PMC1779194          DOI: 10.1136/adc.63.12.1444

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Twelve-minute walking test for assessing disability in chronic bronchitis.

Authors:  C R McGavin; S P Gupta; G J McHardy
Journal:  Br Med J       Date:  1976-04-03

3.  Falsely high peak expiratory flow readings due to acceleration in the mouth.

Authors:  C K Connolly
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

4.  Bronchial lability in cystic fibrosis.

Authors:  G Day; M B Mearns
Journal:  Arch Dis Child       Date:  1973-05       Impact factor: 3.791

5.  Hospital therapy improves exercise tolerance and lung function in cystic fibrosis.

Authors:  F J Cerny; G J Cropp; M R Bye
Journal:  Am J Dis Child       Date:  1984-03

6.  Effect of encouragement on walking test performance.

Authors:  G H Guyatt; S O Pugsley; M J Sullivan; P J Thompson; L Berman; N L Jones; E L Fallen; D W Taylor
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

7.  Two-, six-, and 12-minute walking tests in respiratory disease.

Authors:  R J Butland; J Pang; E R Gross; A A Woodcock; D M Geddes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29

8.  Assessment of respiratory function in patients with chronic obstructive airways disease.

Authors:  I P Mungall; R Hainsworth
Journal:  Thorax       Date:  1979-04       Impact factor: 9.139

9.  Serial changes in pulmonary functions in children hospitalized with cystic fibrosis.

Authors:  G J Redding; R Restuccia; E K Cotton; J G Brooks
Journal:  Am Rev Respir Dis       Date:  1982-07

10.  Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease.

Authors:  C R Swinburn; J M Wakefield; P W Jones
Journal:  Thorax       Date:  1985-08       Impact factor: 9.139

View more
  5 in total

Review 1.  Exercise recommendations for individuals with cystic fibrosis.

Authors:  S R Boas
Journal:  Sports Med       Date:  1997-07       Impact factor: 11.136

2.  Home IV Antibiotic Therapy and Exercise Capacity in Children with CF: A Case Series.

Authors:  Narelle S Cox; Karen O McKay; Jennifer M Follett; Jennifer A Alison
Journal:  Cardiopulm Phys Ther J       Date:  2011-03

3.  Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.

Authors:  Elise Mok; Guy Letellier; Jean-Marie Cuisset; André Denjean; Frédéric Gottrand; Corinne Alberti; Régis Hankard
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

4.  Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia.

Authors:  K P Morris; J Sharp; S Watson; M G Coulthard
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

5.  Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Authors:  J W Witherspoon; R Vasavada; R H Logaraj; M Waite; J Collins; C Shieh; K Meilleur; C Bönnemann; M Jain
Journal:  Eur J Paediatr Neurol       Date:  2018-10-23       Impact factor: 3.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.